Annual CFI
$52.46 M
+$52.11 M+15149.42%
31 December 2021
Summary:
Concert Pharmaceuticals annual cash flow from investing activities is currently $52.46 million, with the most recent change of +$52.11 million (+15149.42%) on 31 December 2021. During the last 3 years, it has risen by +$52.11 million (+15149.42%).CNCE Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$39.10 M
-$74.03 M-211.92%
30 September 2022
Summary:
Concert Pharmaceuticals quarterly cash flow from investing activities is currently -$39.10 million, with the most recent change of -$74.03 million (-211.92%) on 30 September 2022.CNCE Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$54.13 M
-$39.00 M-257.71%
30 September 2022
Summary:
Concert Pharmaceuticals TTM cash flow from investing activities is currently -$54.13 million, with the most recent change of -$39.00 million (-257.71%) on 30 September 2022.CNCE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CNCE Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +10000.0% | -10000.0% | -160.1% |
| 5 y5 years | +38.4% | -887.6% | -231.6% |
CNCE Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -36.5% | -154.9% | -146.3% |
Concert Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$39.10 M(-211.9%) | -$54.13 M(+257.7%) |
| June 2022 | - | $34.93 M(-169.9%) | -$15.13 M(-46.2%) |
| Mar 2022 | - | -$49.95 M(>+9900.0%) | -$28.11 M(-153.6%) |
| Dec 2021 | $52.46 M(>+9900.0%) | -$16.00 K(-83.8%) | $52.46 M(-41.7%) |
| Sept 2021 | - | -$99.00 K(-100.5%) | $90.00 M(-23.0%) |
| June 2021 | - | $21.95 M(-28.3%) | $116.95 M(+29.1%) |
| Mar 2021 | - | $30.62 M(-18.4%) | $90.59 M(>+9900.0%) |
| Dec 2020 | $344.00 K(-99.6%) | $37.52 M(+39.7%) | $344.00 K(-114.0%) |
| Sept 2020 | - | $26.85 M(-709.7%) | -$2.46 M(-89.9%) |
| June 2020 | - | -$4.40 M(-92.6%) | -$24.35 M(+27.3%) |
| Mar 2020 | - | -$59.63 M(-271.7%) | -$19.12 M(-123.2%) |
| Dec 2019 | $82.58 M(+117.9%) | $34.72 M(+599.5%) | $82.58 M(+100.7%) |
| Sept 2019 | - | $4.96 M(+504.6%) | $41.14 M(+43.8%) |
| June 2019 | - | $821.00 K(-98.0%) | $28.61 M(-52.4%) |
| Mar 2019 | - | $42.08 M(-726.5%) | $60.13 M(+58.6%) |
| Dec 2018 | $37.90 M(-131.2%) | -$6.72 M(-11.3%) | $37.90 M(-12.9%) |
| Sept 2018 | - | -$7.58 M(-123.4%) | $43.49 M(-189.6%) |
| June 2018 | - | $32.35 M(+63.0%) | -$48.55 M(-51.9%) |
| Mar 2018 | - | $19.85 M(-1864.3%) | -$101.02 M(-16.7%) |
| Dec 2017 | -$121.31 M | -$1.13 M(-98.9%) | -$121.31 M(+23.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | -$99.62 M(+395.0%) | -$98.24 M(+701.7%) |
| June 2017 | - | -$20.12 M(+4463.3%) | -$12.25 M(-137.4%) |
| Mar 2017 | - | -$441.00 K(-102.0%) | $32.74 M(-553.9%) |
| Dec 2016 | -$7.21 M(-149.5%) | $21.94 M(-261.0%) | -$7.21 M(-117.1%) |
| Sept 2016 | - | -$13.63 M(-154.8%) | $42.09 M(-33.3%) |
| June 2016 | - | $24.87 M(-161.6%) | $63.15 M(-250.0%) |
| Mar 2016 | - | -$40.40 M(-156.7%) | -$42.10 M(-389.0%) |
| Dec 2015 | $14.57 M(-132.8%) | $71.25 M(+859.3%) | $14.57 M(-125.6%) |
| Sept 2015 | - | $7.43 M(-109.2%) | -$56.84 M(+12.2%) |
| June 2015 | - | -$80.38 M(-593.9%) | -$50.65 M(-391.9%) |
| Mar 2015 | - | $16.27 M(<-9900.0%) | $17.35 M(-139.0%) |
| Dec 2014 | -$44.45 M(+1122.2%) | -$165.00 K(-101.2%) | -$44.45 M(+1.8%) |
| Sept 2014 | - | $13.62 M(-210.1%) | -$43.67 M(-42.9%) |
| June 2014 | - | -$12.38 M(-72.8%) | -$76.53 M(+33.5%) |
| Mar 2014 | - | -$45.53 M(-7455.7%) | -$57.32 M(+1475.9%) |
| Dec 2013 | -$3.64 M(+203.1%) | $619.00 K(-103.2%) | -$3.64 M(-14.5%) |
| Sept 2013 | - | -$19.25 M(-381.3%) | -$4.26 M(-128.4%) |
| June 2013 | - | $6.84 M(-16.0%) | $14.99 M(+84.0%) |
| Mar 2013 | - | $8.15 M | $8.15 M |
| Dec 2012 | -$1.20 M(-105.2%) | - | - |
| Dec 2011 | $22.90 M | - | - |
FAQ
- What is Concert Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Concert Pharmaceuticals?
- What is Concert Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Concert Pharmaceuticals?
- What is Concert Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Concert Pharmaceuticals?
What is Concert Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of CNCE is $52.46 M
What is the all time high annual CFI for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high annual cash flow from investing activities is $82.58 M
What is Concert Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of CNCE is -$39.10 M
What is the all time high quarterly CFI for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high quarterly cash flow from investing activities is $71.25 M
What is Concert Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of CNCE is -$54.13 M
What is the all time high TTM CFI for Concert Pharmaceuticals?
Concert Pharmaceuticals all-time high TTM cash flow from investing activities is $116.95 M